FDA Crackdown on Compounded GLP-1s Lifts Novo, Lilly

The FDA sent warning letters to several telehealth companies this week. The letters tell the firms to stop marketing compounded versions of Novo Nordisk's Ozempic and Eli Lilly's Mounjaro as "generic" or "bioidentical" to the brand-name drugs. The agency said those claims mislead patients and violate federal law.

Compounded drugs are not FDA-approved copies. They are custom-mixed versions made when a patient has a medical need the approved drug cannot meet. An allergy to a dye or a dosage strength not available on the market are examples. The telehealth companies named in the letters were selling compounded semaglutide and tirzepatide as direct substitutes, often at lower prices, without a valid patient-specific prescription, the FDA said.

The crackdown matters for Novo Nordisk and Eli Lilly because compounded GLP-1s have been eating into their market share. The drugs have been in short supply. Compounding pharmacies filled the gap. The FDA's letters signal that the agency is tightening enforcement. That could push patients back toward the branded products.

Novo Nordisk's stock page shows an Alpha Score of 56, reflecting moderate positioning. Eli Lilly's stock page scores 75, also moderate. Both companies have been racing to increase production capacity. Supply constraints have persisted. The FDA's move removes one source of competition, at least for patients who were buying compounded versions without a documented medical need.

The telehealth firms named in the letters have 15 days to respond with corrective actions. The FDA said it will consider further enforcement steps, including seizures or injunctions, if the violations continue.

For Novo Nordisk and Eli Lilly, the immediate read-through is straightforward. Less competition from unapproved copies means more patients staying on or switching to the branded drugs. The longer-term question is whether the compounding industry will shift to a compliant model. That would mean filling only legitimate patient-specific prescriptions. Or the FDA may need to escalate.

The regulatory environment just got tighter for the compounders. For the incumbents, the path is clearer.